Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

BTOG 2025 | Treating adverse symptoms of brain metastasis in lung cancer

John Conibear • 3 Mar 2025
BTOG 2025
Lung Cancer

John Conibear, MBBCh, BSc, MSc, MRCP, FRCR, Nottingham City Hospital, Nottingham, UK, discusses the impact of brain metastasis on quality of life. Treatments such as stereotactic radiosurgery to reduce tumour volume are critical in improving symptoms and overall survival (OS). This interview took place at the BTOG 2025 congress in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from John Conibear

The future of small-molecule drugs in NSCLC
0:52
The future of small-molecule drugs in NSCLC
John Conibear • 3 Mar 2025
Advances in first-line NSCLC treatments
1:04
Advances in first-line NSCLC treatments
John Conibear • 3 Mar 2025
Key highlights from BTOG 2023: radiotherapy at the forefront
2:11
Key highlights from BTOG 2023: radiotherapy at the forefront
John Conibear • 4 May 2023
Lessons learnt from a UK lung SABR rollout program
0:56
Lessons learnt from a UK lung SABR rollout program
John Conibear • 8 Jul 2022

Related Videos

Follow-up to the MODERN-LUNG trial of hypofractionated radiotherapy in lung cancer
1:32
Follow-up to the MODERN-LUNG trial of hypofractionated radiotherapy in lung cancer
Shalini Vinod • 17 May 2026
Can radiotherapy treatment burden be reduced for patients with lung cancer?
0:45
Can radiotherapy treatment burden be reduced for patients with lung cancer?
Shalini Vinod • 17 May 2026
One-Stop SABR: same-day sim-plan-and-treat single fraction SABR for early lung cancer
1:59
One-Stop SABR: same-day sim-plan-and-treat single fraction SABR for early lung cancer
Neil Wallace • 16 May 2026
Efficacy and safety of single-fraction SABR for primary NSCLC and lung oligometastases
2:21
Efficacy and safety of single-fraction SABR for primary NSCLC and lung oligometastases
Neil Wallace • 16 May 2026
The content of VJOncology is intended for healthcare professionals